Literature DB >> 26742474

Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).

Thomas D Cook1, Stephen J Greene2, Andreas P Kalogeropoulos3, Gregg C Fonarow4, Ryan Zea1, Karl Swedberg5, Faiez Zannad6, Aldo P Maggioni7, Marvin A Konstam8, Mihai Gheorghiade9, Javed Butler10.   

Abstract

In observational studies of patients hospitalized for heart failure (HHF), risk of death is highest immediately after discharge and decreases over time. It is unclear whether this population risk trajectory reflects (1) lowering of individual patient mortality risk with increasing time from index hospitalization or (2) temporal changes in population case-mix with earlier postdischarge death for "sicker" patients. Survival rate and longitudinal models were used to estimate temporal changes in postdischarge all-cause mortality risk in 3,993 HHF patients discharged alive in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. After median follow-up of 9.9 months, 971 patients died (24.2%). Predicted mortality rate decreased from 15.9 per 100 patient-years immediately after discharge to 13.4 at 30 days and 12.8 at 90 days; mortality rate increased steadily thereafter. Risk variation between quintiles of risk was considerably larger than the temporal variation within risk strata. In a longitudinal model serially reassessing predicted patient mortality risk after each follow-up visit using data collected at these visits, predicted mortality risk increased during the 90 days preceding subsequent heart failure readmission and then followed a postdischarge trajectory similar to the index admission. In conclusion, although there is transiently elevated individual patient risk in the 90 days before and after discharge, the patient's individual risk profile, rather than temporal change in risk relative to hospitalization, remains the main determinant of mortality. For purposes of reducing all-cause mortality in HF patients, preventative and therapeutic measures may be best implemented as long-term interventions for high mortality risk patients based on serial risk assessments, irrespective of recent hospitalization.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26742474     DOI: 10.1016/j.amjcard.2015.11.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.

Authors:  Stephen J Greene; G Michael Felker; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-11-05       Impact factor: 15.534

2.  Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Matteo Beltrami; Ranuccio Nuti; John G Cleland
Journal:  Clin Res Cardiol       Date:  2018-03-12       Impact factor: 5.460

3.  Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Authors:  Stephen J Greene; Robert J Mentz; G Michael Felker
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

Review 4.  Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations.

Authors:  Alexandra Arvanitaki; Eleni Michou; Andreas Kalogeropoulos; Haralambos Karvounis; George Giannakoulas
Journal:  ESC Heart Fail       Date:  2020-05-05

5.  Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital?

Authors:  Stephen J Greene; G Michael Felker
Journal:  JACC Basic Transl Sci       Date:  2018-03-01

6.  Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis.

Authors:  Renato Guerreiro; Célia Henriques; Sara Trevas; Cláudio Gouveia; Marta Roldão; Inês Egídio de Sousa; Catarina Faria; Gonçalo Pimenta; Inês Araújo; Candida Fonseca
Journal:  Cureus       Date:  2022-01-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.